1-7 of 7
Jichao Sun, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139868
Published: 2020
Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2662.
https://doi.org/10.1182/blood-2019-125966
Published: 2019
Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, Cedric Viero, PhD, John Godwin, MD, Jan Baughman, MPH, Jichao Sun, PhD, Kang Ying, John Muth, MS, Shengyan Hong, PhD, Norbert Vey, MD PhD, Kendra L. Sweet, MD, Geoffrey L. Uy, MD, Farhad Ravandi, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P. Rettig, PhD, Max S. Topp, Gerwin Huls, MD PhD, Helene Lelièvre, PhD PharmD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2738.
https://doi.org/10.1182/blood-2018-99-112615
Published: 2018
Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Norbert Vey, MD PhD, John Godwin, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, Gerwin Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra L. Sweet, MD, Farhad Ravandi, MD, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD PhD FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La Motte-Mohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Lowenberg, MD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 764.
https://doi.org/10.1182/blood-2018-99-117085
Published: 2018
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017